On August 19, 2026, Femasys Inc. (Nasdaq: FEMY) announced that the U.S. Food and Drug Administration had approved a modular premarket approval (PMA) submission pathway for FemBloc, the Georgia company's investigational non-surgical permanent birth control technology. The modular approach is a procedural win rather than a clinical one — it lets Femasys submit and have FDA review discrete components of its PMA application in advance of the final clinical data package, rather than waiting to assemble one monolithic filing at the end of the trial. For a small-cap device company running a long enrollment clock, that timing difference matters, and investors read it that way: FEMY shares rallied sharply on the news.

Why It Matters

Permanent contraception is one of the few large women's-health categories where the standard of care has barely moved in decades and where the last major innovation attempt ended badly — Bayer's Essure hysteroscopic implant was pulled from the U.S. market in 2018 after years of adverse-event reports and litigation. Any new entrant in tubal occlusion is therefore walking into a regulatory environment shaped by that history, which is precisely why FDA's willingness to grant a modular review is notable: it signals the agency is prepared to engage iteratively rather than making the sponsor guess at the finish line. The demand backdrop is also unusually sharp. Interest in permanent contraception in the U.S. rose measurably after the 2022 Dobbs decision, and access is unevenly distributed — surgical sterilization requires facility access, anesthesia coverage, and time off work that many patients simply cannot arrange. An office-based, anesthesia-free option would move the procedure into the same setting where most patients already get their annual exam. For the femtech investment thesis, FemBloc is a useful test of whether a genuinely novel reproductive-health device can clear a Class III regulatory bar without the capital base of a large strategic behind it.

FemBloc is designed to do in an OB/GYN office what tubal ligation currently requires an operating room to accomplish. The system pairs a patented delivery catheter with a separately patented blended polymer that is placed into both fallopian tubes, where it degrades and prompts the formation of natural scar tissue to permanently occlude the tubes. There is no anesthesia, no incision, and no recovery period. Femasys frames that as both a convenience and a cost story — surgical sterilization carries operating-room expense, general anesthesia risk, and days of downtime that fall hardest on the patients least able to absorb them.

"This modular PMA approach is an important step forward for FemBloc toward U.S. approval, allowing key components of the submission to be reviewed by FDA in advance of the final clinical data," said Kathy Lee-Sepsick, Femasys' Chief Executive Officer and Founder, in the company's announcement. Lee-Sepsick also flagged a parallel commercial build: Femasys is assembling a U.S. sales team to push its existing fertility portfolio — the FemaSeed intratubal insemination device and FemVue diagnostic among them — beyond fertility specialists and into general OB/GYN practices. That same team is intended to eventually carry FemBloc, giving the company an existing channel on day one of approval rather than a standing start.

FemBloc is not a hypothetical product everywhere. Femasys says the technology already received regulatory approvals in Europe, the UK, and New Zealand during 2025 and is being commercialized internationally through partnerships. The U.S. remains the prize and the bottleneck: the clinical program is still enrolling, the PMA is not filed in full, and the company's own forward-looking disclosures note that approval and revenue are contingent on the trial demonstrating safety and effectiveness. This is a milestone on a path, not the end of one.

Sources

Update — 2026-08-23

{Initial entry — story first created.}